This is the future


Anonymous

Guest
We do have year now on Plavix with the extension...maybe 15 months
Onglyza/Kombiglyze XR will never be big revenue generators.....the market does not tolerate me too drugs anymore
Dapa... is a big if , new drugs are, but at least a novel MOA
Eliquis...3rd in class? maybe? same fate as Onglyza

big changes are coming...maybe a merger...who knows
but when the Plavix bank closes.....the world as we know it is over
with Onglyza lack of sales, Avapro's demise and Plavix being self sustaining we are not nearly generating enough income to pay our own salaries...it cannot continue

A sad overview, but it is the same for all companies riding a blockbuster drug

Let's not forget Abilify is in trouble from looming Seroquel and Zyprexa generics